Ishii H, Niiya T, Ono Y, et al
Unlike GLP-1, some studies demonstrated that the glucanotropic effects of GIP was present in the normoglycaemic and hypoglycaemic state and was unclear in the hyperglycaemic state [15]
Trial registration European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 2019-000781-38 Graphical Abstract Similar content being viewed by others Introduction Chronic kidney disease (CKD) represents a serious and increasingly prevalent complication occurring in 3040% of individuals with type 2 diabetes [1]
Retatrutide reconstitution chart Vial Size 5 mg BAC Water 1.0 mL Concentration 5 mg/mL (5,000 mcg/mL) 1 mg 0.20 mL (20 units) 2 mg 0.40 mL (40 units) 4 mg 0.80 mL (80 units) 6 mg Exceeds vial 9 mg Exceeds vial 12 mg Exceeds vial Vial Size 10 mg BAC Water 2.0 mL Concentration 5 mg/mL (5,000 mcg/mL) 1 mg 0.20 mL (20 units) 2 mg 0.40 mL (40 units) 4 mg 0.80 mL (80 units) 6 mg 1.20 mL - split draw or 2 vials 9 mg Requires 2 vials 12 mg Requires 2-3 vials Vial Size 20 mg BAC Water 2.0 mL Concentration 10 mg/mL (10,000 mcg/mL) 1 mg 0.10 mL (10 units) 2 mg 0.20 mL (20 units) 4 mg 0.40 mL (40 units) 6 mg 0.60 mL (60 units) 9 mg 0.90 mL (90 units) 12 mg 1.20 mL - split draw Vial Size 24 mg BAC Water 2.4 mL Concentration 10 mg/mL (10,000 mcg/mL) 1 mg 0.10 mL (10 units) 2 mg 0.20 mL (20 units) 4 mg 0.40 mL (40 units) 6 mg 0.60 mL (60 units) 9 mg 0.90 mL (90 units) 12 mg 1.20 mL - split draw Vial Size 30 mg BAC Water 3.0 mL Concentration 10 mg/mL (10,000 mcg/mL) 1 mg 0.10 mL (10 units) 2 mg 0.20 mL (20 units) 4 mg 0.40 mL (40 units) 6 mg 0.60 mL (60 units) 9 mg 0.90 mL (90 units) 12 mg 1.20 mL - split draw Units are U-100 insulin syringe units (1 mL = 100 units)
No more than any other area
For the medical device industry, the consequences of the GLP-1 revolution could be devastating indeed
)
